Often regarded as a secondary care priority, venous thromboembolism is being targeted by some innovative new treatments which are producing huge savings for the NHS
In this HSJ supplement, in association with Bayer HealthCare, the treatment of venous thromboembolism is discussed.
The first chapter looks at the new treatments and pioneering trusts showing how VTE can be managed differently than just as secondary care.
The case studies show how one Bradford GP’s “light bulb moment” led to radical change in his local health economy, prompting the treatment of deep vein thrombosis to shift out of hospital.
Also analysed is Bristol GPs’ frustration with a secondary care system that made DVT patients wait days to start treatment. Their efforts prompted the creation of a new community based pathway that is producing huge savings for the NHS.
The PDF of this supplement is no longer available to download.
- Also this week: Special report on the sticking point for medication adherence